FDA approves first-in-class cancer metabolism drug

Nature Reviews Drug Discovery 16, 593 (2017). doi:10.1038/nrd.2017.174 Author: Asher Mullard The FDA approved Agios' and Celgene's enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells.Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research